Skip to content

Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting

Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting - - a Randomized Controlled Study

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07012863
Enrollment
650
Registered
2025-06-10
Start date
2026-01-01
Completion date
2027-09-30
Last updated
2025-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Rupture, Bleeding, Blunt Injury, Gastrointestinal Hemorrhage, Obstetric Bleeding, Penetrating Injury

Brief summary

The overall goal of this clinical trial is to study how prehospital transfused dry plasma affect outcomes in terms of mortality as well as complications and coagulation status of patients in or about to develop bleeding shock. Researchers will compare dry plasma to standard care to see if dry plasma improves survival compared to crystalloid fluid in prehospital patients with heavy bleeding.

Detailed description

Major haemorrhage remains one of the leading causes of preventable early death after injury, and the window for effective intervention often closes in the pre-hospital phase. Contemporary European guidelines therefore advocate damage-control resuscitation: permissive hypotension, minimal crystalloid use and early infusion of blood components to avoid dilutional coagulopathy, acidosis and hypothermia. Several reports support that early resuscitation with blood products may save lives. Freeze- or spray dried plasma containing coagulation factors having up to two years storage time and the possibility of storing ambient temperature, may be an alternative to crystalloids. The results regarding the beneficial results of treatment with plasma are ambiguous. In a previous randomized study using fresh plasma versus crystalloids, 9,8% reduced mortality was shown with resuscitation with plasma. Lower INR and lactate were also seen among the patients treated with plasma. In some studies no effect on mortality could be shown, but in other studies it is suggested that plasma may be beneficial in long transport time. Acute traumatic coagulopathy can be seen in at least 25 % of severely injured patients who are admitted to a trauma centre. Dilution is often considered as a likely cause although the exact mechanisms and level of aggravation is unknown. Most studies of prehospital bleeding refer to trauma, but also other causes of bleeding can be severe and even fatal, especially in countries with long distances, e.g. obstetric bleeding, gastrointestinal bleeding and vascular catastrophes. Hypothesis. The hypothesis of this study is that prehospital treatment with dry plasma to bleeding patients improves the outcome compared to patients receiving standard treatment in terms of lower mortality, lower degree of coagulopathy and less need for blood products when in hospital. Study aim. The aim of this study is to report outcome for patients receiving standard treatment for major prehospital bleeding compared to patients receiving standard care and to report clinical data for both groups.

Interventions

BIOLOGICALDry plasma

Patient that fulfil the inclusion criteria for this study and are randomized for active treatment will get dry plasma as intervention.

Sponsors

Vastra Gotaland Region
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with clinical signs of bleeding which also triggers resuscitation with crisalloids acording to standard care protocol.

Exclusion criteria

* Patients \< 18 years of age. * Patients who lack clinical signs of major bleeding.

Design outcomes

Primary

MeasureTime frameDescription
MortalityWithin 24 hours after hospital admission.Overall mortality at 24 hours after hospital admission. Will include patients dead at scene or during transportation.

Secondary

MeasureTime frameDescription
Mortality for patients with bleeding > 500 mL (milliliter)Within 24 hours after hospital admissionSpecific mortality for patients with a bleeding \> 500mL at 24 hours after hospital admission. Will include patients dead at scene or during transport.
Shock Indexbaseline, pre-intervention at sceneShock Index \> 1.3.
Coagulopathy overallMeasured at hospital admissionPK/INR \> 1.2 and/or Platelet count \< 150 x 109/L and/or APTT \> 34 s or each valuable alone. INR= international normalized ratio PK= prothrombin complex. APTT= activated partial thromboplastin time.

Contacts

Primary ContactGöran Sandström, PhD
goran.sandstrom@gu.se+46760181284
Backup ContactGabriel Skallsjö, MD
gabriel.skallsjo@vgregion.se+46705683196

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026